NCT03154944

Brief Summary

This investigation evaluates three new ostomy appliances and their impact on the peristomal skin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2017

Completed
Same day until next milestone

Study Start

First participant enrolled

May 15, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 16, 2017

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 2, 2018

Completed
7.2 years until next milestone

Results Posted

Study results publicly available

March 28, 2025

Completed
Last Updated

March 28, 2025

Status Verified

March 1, 2025

Enrollment Period

9 months

First QC Date

May 15, 2017

Results QC Date

October 2, 2023

Last Update Submit

March 7, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Trans Epidermal Water Loss

    The trans epidermal water loss is measured on the peristomal skin using a probe. The Tran epirdermal water loss is a maesure for the skins barrier function. There is always a loss of water from the skin due to natural evaporation. However, when the skin barrier is damaged the evaporation of water increases leading to a higher trans epidermal water loss. Thus, trans epidermal water loss is used to assess the damage to the skin. Measurements are in grams of water per square meter per hour (g/m\^2/h).

    7 days

Study Arms (3)

Ostomy device 1

EXPERIMENTAL

In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film

Device: Ostomy device 1

Ostomy device 2

EXPERIMENTAL

In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film

Device: Ostomy device 2

Ostomy device 3

EXPERIMENTAL

In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film

Device: Ostomy device 3

Interventions

This device consists of a known adhesive and a new top film

Ostomy device 1

This device consists of a new adhesive and a known top film

Ostomy device 2

This device consists of a known adhesive and a new top film

Ostomy device 3

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have given written informed consent and in DK: signed a letter of authority
  • Be at least 18 years of age and have full legal capacity
  • Have had their ileostomy for at least 3 months
  • Have an ileostomy with a diameter between 10 and 55 mm
  • Be able to handle the Clinical App. and product themselves
  • Must be able to use custom cut product
  • Minimum change of product every second day
  • If current product is SenSura Mio - Be willing to use Maxi bag during investigation
  • Negative result of a pregnancy test for women of childbearing age (only DK)

You may not qualify if:

  • Are currently receiving or have within the past 2 months received radio-and/or chemotherapy (low doses chemotherapy are allowed for other indications than cancer, e.g. below 15 mg methotrexate for rheumatoid arthritis)
  • Are currently receiving or have within the past month received topical steroid treatment in the peristomal skin area, e.g. lotion or spray. Systemic steroid treatment (e.g. injection, or tablet) are allowed.
  • Are pregnant or breastfeeding\*\*
  • Are participating in other interventional clinical investigations or have previously participated in this investigation
  • Are currently suffering from peristomal skin problems i.e. bleeding and/or broken skin (assessed by the investigator)
  • Have known hypersensitivity towards any of the products used in the investigation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Coloplast A/S

Humlebæk, 3050, Denmark

Location

Results Point of Contact

Title
Head of Medical Writing and Biostatistics
Organization
Coloplast

Study Officials

  • Birte P Jakosen, MD

    Medial director

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 15, 2017

First Posted

May 16, 2017

Study Start

May 15, 2017

Primary Completion

February 2, 2018

Study Completion

February 2, 2018

Last Updated

March 28, 2025

Results First Posted

March 28, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations